Skip to main content
Top
Published in: PharmacoEconomics 8/2008

01-08-2008 | Commentary

Waiting for Reimbursement of New Medicines in Canada

It’s Time for a Rethink

Author: Brett J. Skinner

Published in: PharmacoEconomics | Issue 8/2008

Login to get access

Abstract

Available evidence indicates that patients who have private sector drug insurance are immediately covered for all new medically necessary drugs certified by Health Canada, with few exceptions. The experience for patients who are dependent on public drug programmes is much worse. Evidence indicates that, on average across the provinces, far less than half of the drugs certified by Health Canada are finally approved by the provinces for public reimbursement. Publicly insured patients also wait up to 1 year longer than privately insured patients to get insurance coverage for new drugs. Evidence also shows that public drug coverage varies widely across provinces.
Footnotes
1
Some private plans exclude ‘non-medically necessary’‘life-style’ drugs.
 
2
‘Pharmaceutical’ drugs are chemical-based products; ‘biological’ drugs are biochemical-based products.
 
3
There are three classes of non-generic new drug approval submissions: new active substances, new drug submissions and supplemental new drug submissions.
 
Literature
1.
go back to reference DiMasi JA. Risks in new drag development: approval success rates for investigational drags. Clin Pharmacol Ther 2001: 69 (5): 297–307PubMedCrossRef DiMasi JA. Risks in new drag development: approval success rates for investigational drags. Clin Pharmacol Ther 2001: 69 (5): 297–307PubMedCrossRef
2.
go back to reference Adams CP, Brantner VV. New drag development: estimating entry from human clinical trials [US Federal Trade Commission working paper 262]. Washington, DC: US FTC, 2003 Adams CP, Brantner VV. New drag development: estimating entry from human clinical trials [US Federal Trade Commission working paper 262]. Washington, DC: US FTC, 2003
3.
go back to reference Adams CP, Brantner VV. Estimating the cost of new drag development: is it really $802 million? Health Aff 2006; 25 (2): 420–428CrossRef Adams CP, Brantner VV. Estimating the cost of new drag development: is it really $802 million? Health Aff 2006; 25 (2): 420–428CrossRef
4.
go back to reference DiMasi JA, Hansen RW, Grabowski HG, et al. Research and development costs for new drags by therapeutic category: a study of the US pharmaceutical industry. Pharmacoeconomics 1995; 7 (2): 152–169PubMedCrossRef DiMasi JA, Hansen RW, Grabowski HG, et al. Research and development costs for new drags by therapeutic category: a study of the US pharmaceutical industry. Pharmacoeconomics 1995; 7 (2): 152–169PubMedCrossRef
5.
go back to reference DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drag development costs. J Health Econ 1993; 22 (2): 151–185CrossRef DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drag development costs. J Health Econ 1993; 22 (2): 151–185CrossRef
10.
go back to reference Newhouse JP, Keeler EB, Willard Jr GM, et al. Free for all? Lessons from the RAND health insurance experiment: a RAND study. Cambridge (MA): Harvard University Press, 1993 Newhouse JP, Keeler EB, Willard Jr GM, et al. Free for all? Lessons from the RAND health insurance experiment: a RAND study. Cambridge (MA): Harvard University Press, 1993
Metadata
Title
Waiting for Reimbursement of New Medicines in Canada
It’s Time for a Rethink
Author
Brett J. Skinner
Publication date
01-08-2008
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2008
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200826080-00001

Other articles of this Issue 8/2008

PharmacoEconomics 8/2008 Go to the issue

Current Opinion

Modelling Approaches

Adis Pharmacoeconomic Drug Evaluation

Trastuzumab